Thierry Lecomte
Overview
Explore the profile of Thierry Lecomte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
191
Citations
3724
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lecomte T, Giraudeau B, Phelip J, Tournigand C, Ducreux M, Tougeron D, et al.
Dig Liver Dis
. 2025 Mar;
PMID: 40044552
Bevacizumab shows inter-individual pharmacokinetic variability, with an exposure-response relationship in metastatic colorectal cancer (mCRC) patients. This study explores whether a double dose of bevacizumab, compared to a standard dose, increases...
2.
Adamus N, Edeline J, Henriques J, Fares N, Lecomte T, Turpin A, et al.
JHEP Rep
. 2025 Feb;
7(2):101279.
PMID: 39897613
Background & Aims: Selective internal radiation therapy (SIRT) is a promising option for liver-only unresectable intrahepatic cholangiocarcinoma (iCCA). The Real-SIRTCCA study retrospectively assessed the benefit of adding SIRT to chemotherapy...
3.
Suspene R, Raymond K, Guardado-Calvo P, Dairou J, Bonhomme F, Bonenfant C, et al.
J Biol Chem
. 2024 Dec;
301(2):108117.
PMID: 39722416
Perturbation of the deoxyribonucleotide triphosphate (dNTP) pool is recognized for contributing to the mutagenic processes involved in oncogenesis. The RAS gene family encodes well-characterized oncoproteins whose structure and function are...
4.
Dabout V, Mineur L, Tougeron D, Le Malicot K, Gallois C, Phelip J, et al.
Clin Res Hepatol Gastroenterol
. 2024 Dec;
49(1):102514.
PMID: 39674570
Aim Of The Study: The management of synchronous metastatic rectal cancer (SMRC) is complex and multimodal, involving chemotherapy, surgery and/or radiotherapy. The aim of this study was firstly to confirm...
5.
Walter T, Lecomte T, Hadoux J, Niccoli P, Saban-Roche L, Gaye E, et al.
J Clin Oncol
. 2024 Nov;
43(8):960-971.
PMID: 39586038
Purpose: Alkylating agents (ALKY) are the main chemotherapies used for advanced neuroendocrine tumors (NETs). O-Methylguanine-DNA methyltransferase (MGMT) status, as proficient (p) or deficient (d), may predict the response to ALKY....
6.
Bach C, Tallet A, Bonenfant C, Lecomte T, Piton N, Samimi M, et al.
Virchows Arch
. 2024 Nov;
PMID: 39579263
Recurrent mutations in the CTNNB1 or APC genes leading to the activation of the Wnt/betacatenin pathway are observed in adnexal tumors with matrical differentiation. While most pilomatricomas arise sporadically and...
7.
Tougeron D, Bibeau F, Chibaudel B, Kim S, Nguyen T, Phelip J, et al.
Eur J Cancer
. 2024 Nov;
213():115082.
PMID: 39486163
Aim: To evaluate R0/R1 resection rate in patients with colorectal liver metastases (CLM) treated with aflibercept plus FOLFIRI after failure of a prior oxaliplatin-based regimen in daily clinical practice. Methods:...
8.
Robert A, Crottes D, Bourgeais J, Gueguen N, Chevrollier A, Dumas J, et al.
PLoS Biol
. 2024 Oct;
22(10):e3002854.
PMID: 39466877
The mitochondrial Ca2+ uniporter (MCU) plays crucial role in intramitochondrial Ca2+ uptake, allowing Ca2+-dependent activation of oxidative metabolism. In recent decades, the role of MCU pore-forming proteins has been highlighted...
9.
Boisteau E, Dahan L, Williet N, Le Malicot K, Desrame J, Bouche O, et al.
Oncologist
. 2024 Sep;
29(9):e1149-e1158.
PMID: 39235326
Introduction: Predictive markers of LV5FU2 maintenance benefit after first-line induction with FOLFIRINOX in patients with metastatic pancreatic cancer are necessary to select patients who will not be harmed by this...
10.
Chautard R, Caulet M, Bouche O, Borg C, Manfredi S, Capitain O, et al.
Dig Liver Dis
. 2024 Aug;
57(1):141-148.
PMID: 39164167
Background And Aims: Bevacizumab-based chemotherapy is a recommended first-line treatment for metastatic colorectal cancer (mCRC). Robust biomarkers with clinical practice applicability have not been identified for patients with this treatment....